Importance of Caregivers for Patients with Multiple Myeloma | Hamza Hashmi | ASH 2023

Importance of Caregivers for Patients with Multiple Myeloma | Hamza Hashmi | ASH 2023
Serum Biomarkers and Progression Risk in Smoldering Myeloma | Theresia Akhalghi, MD | ASH 2023
Pathogenic Germline Variants in Cancer Predisposition Genes | Santiago Thibaud, MD | ASH 2023
Unscheduled Interactions in Outpatient Bispecific Therapy for RRMM | Anna Howard, RN | ASH 2023
Benefits of Early MGUS Screening: iStopMM Study Results | Sæmundur Rögnvaldsson, MD, PhD | ASH 2023
GPRC5D Directed CAR T-Cell Therapy | University of Alabama | Susan Bal, MD | ASH 2023
Teclistamab: Outpatient Step-up Dosing and Real-World Outcomes | Tyler Sandahl, PharmD | ASH 2023
Insurance Impact on Outcomes for Rural Hematologic Patients | Kingsley Nnawuba, MD | ASH 2023
Real-World Safety and Efficacy of Teclistamab | Hamza Hashmi | ASH 2023
Efficacy of Reduced Dosing of Talquetamab in Relapsed Refractory Myeloma | Ajai Chari, MD | ASH 2023
Myeloma Treatment Comparison: RVd vs. D-RVd Outcomes | Nisha Joseph, MD | ASH 2023
Updated Safety and Efficacy Results of ABBV-383 | Ravi Vij, MD, MBA | ASH 2023
MGUS and Thrombotic Events: iStopMM Study Results | Sæmundur Rögnvaldsson, MD, PhD | ASH 2023